Similar Papers

Paper Title
Journal
Date
Author
Abstract OT3-1-04: A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer (SONG-02)
Hajime Abe ... Keiichi Yamazaki
Cancer Research | VOL. 75
Hajime Abe, et. al.Hajime Abe ... Keiichi Yamazaki
30 Apr 2015
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
Koichi Sakaguchi ... Yuji Yoshino
Anticancer Research | VOL. 38
Koichi Sakaguchi, et. al.Koichi Sakaguchi ... Yuji Yoshino
01 Jul 2018
Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
M Spanggaard ... M Anderson
BMC Health Services Research | VOL. 22
M Spanggaard, et. al.M Spanggaard ... M Anderson
04 Jun 2022
Abstract OT-03-04: Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
Fabrice Andre ... Pia Herbolsheimer
Cancer Research | VOL. 81
Fabrice Andre, et. al.Fabrice Andre ... Pia Herbolsheimer
15 Feb 2021
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update
N.I Cherny ... E.G.E De Vries
Annals of Oncology | VOL. -
N.I Cherny, et. al.N.I Cherny ... E.G.E De Vries
01 Jan 2025
The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study
E Rangelova ... Y Kimura
Annals of Oncology | VOL. -
E Rangelova, et. al.E Rangelova ... Y Kimura
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.